Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer

Chartwell Partners is pleased to have worked with our long-standing client, Akebia Therapeutics, to recruit Mr. Ostrowski as Chief Financial Officer and Chief Business Officer. Mr. Ostrowski is an important addition to Akebia’s leadership team as the Company executes its US launch of Vafeso® for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. Vafseo is approved in 37 countries. Mr. Ostrowski brings a breadth of leadership experience from the biopharmaceutical industry, investment banking and board service.

Mr. Ostrowski joins Akebia from Avrobio, where he served as President, Interim Chief Executive Officer and Chief Financial Officer, leading the execution of its merger with Tectonic Therapeutic. Prior to Avrobio, Mr. Ostrowski was Chief Financial Officer of Summit Therapeutics where he led its initial public offering on Nasdaq. He was recently Chair of the Audit Committee of the Board of Directors of Faron Pharmaceuticals. Mr. Ostrowski also spent over ten years in investment banking including at Leerink Partners and Robertson Stephens. Mr. Ostrowski earned his bachelor’s degree in accounting and economics from Babson College and an MBA from the University of Chicago Booth School of Business.